Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

Hyperemesis Gravidarum and Nutritional Support
Elkins, Jaclyn R., Nguyen, Linda Anh B., Oxentenko, Amy S.

Mayo Clinic

American Journal of Gastroenterology | October 4, 2022 | Volume: 117 | Issue: 10S | Pages: 2-9

10.14309/ajg.0000000000001957 | PMID 36194027 Get It

Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
Nguyen, Mindie H. , Roberts, Lewis R. , Engel-Nitz, Nicole, Bancroft, Tim , Singal, Amit G. , Singal, Amit , Roberts, Lewis R , Ozbay, A. Burak

Mayo Clinic

Hepatology Communications | September 30, 2022 | Volume: 6 | Issue: 12 | Pages: 3443-3456

10.1002/hep4.2087 | PMID 36178256 Get It

Abstract Suboptimal adherence to guidelines for hepatocellular carcinoma (HCC) surveillance among high‐risk patients is a persistent problem with substantial detriment to patient outcomes. While patients cite cost as a barrier to surveillance receipt, the financial burden they experience due to surveillance has not been examined. We conducted a retrospective administrative claims study to assess HCC surveillance use and associated costs in a US cohort of insured patients without cirrhosis but with hepatitis B virus (HBV) infection, monitored in routine clinical practice. Of 6831 patients (1122 on antiviral treatment, 5709 untreated), only 39.3% and 51.3% had received any abdominal imaging after 6 and 12 months, respectively, and patients were up to date with HCC surveillance guidelines for only 28% of the follow‐up time. Completion of surveillance was substantially higher at 6 and 12 months among treated patients (51.7% and 69.6%, respectively) compared with untreated patients (36.9% and 47.6%, respectively) ( p < 0.001). In adjusted models, treated patients were more likely than untreated patients to receive surveillance (hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.53–2.01, p < 0.001), and the proportion of those up to date with surveillance was 9.7% higher (95% CI 6.26–13.07, p < 0.001). Mean total and patient‐paid daily surveillance‐related costs ranged from $99 (ultrasound) to $334 (magnetic resonance imaging), and mean annual patient costs due to lost productivity for surveillance‐related outpatient visits ranged from $93 (using the federal minimum wage) to $321 (using the Bureau of Labor Statistics wage). Conclusion : Use of current HCC surveillance strategies was low across patients with HBV infection, and surveillance was associated with substantial patient financial burden. These data highlight an urgent need for accessible and easy‐to‐implement surveillance strategies with sufficient sensitivity and specificity for early HCC detection.
The American Foregut Society White Paper on the Endoscopic Classification of Esophagogastric Junction Integrity
Nguyen, Ninh T. , Chang, Kenneth J. , Lipham, John C. , Dayyeh, Barham Abu, Wilson, Erik B., Muthusamy, V. Raman, Bell, Reginald , Janu, Peter , Runge, Ava , Thosani, Nirav C , Canto, Marcia Irene , Muthusamy, V. Raman , Clarke, John O. , Swanström, Lee L. , Kahrilas, Peter J.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | September 29, 2022 | Volume: 2 | Issue: 4 | Pages: 339-348

10.1177/26345161221126961 Get It

Background: The American Foregut Society (AFS) is dedicated to advancing patient care and digestive health within the realm of foregut disease. One of the most common and debilitating esophageal conditions is gastroesophageal reflux disease (GERD). The Hill grade is an endoscopic classification of the esophagogastric junction (EGJ) based on the appearance of the gastroesophageal flap valve from a retroflexed view of the hiatus. This endoscopic classification provides insight into the anatomic disruption of the EGJ which has been shown to correlate with GERD. However, clinical utilization of this classification by endoscopists has been limited due to the perceived relevance and subjectivity of the classification. With the advent of endoscopic treatment options for GERD, there is renewed enthusiasm to develop a grading system of the EGJ that can objectively define anatomical impairment and reduce interobserver grading variability. Methods: The AFS convened a 13-member working group tasked with reviewing the Hill grade classification and formulating a proposal for its revision utilizing a modified Delphi method. This white paper summarizes the output from this working group. Results: The working group concluded that all components of the antireflux barrier—the lower esophageal sphincter and its sling fibers, the crural diaphragm, and the gastroesophageal flap valve—contribute to EGJ integrity. Using defined objective parameters of extent of hiatal axial herniation and crural disruption and presence or absence of a flap valve, the new AFS classification stratifies EGJ integrity from normal (grade 1) to increasing degrees of EGJ disruption (grade 2-4) beginning with loss of the flap valve and progressing to increasing degrees of crural disruption and hiatus hernia. This AFS classification also stipulates appropriate endoscopic methodology to utilize in making the assessment and provides a basic nomenclature for communication among endoscopists. Conclusions: The AFS endoscopic classification of the EGJ expands on the Hill classification by including assessment of axial hiatal hernia length (L), hiatal aperture diameter (D), and presence or absence of the flap valve (F) making it more comprehensive - LDF components. Future directions include validation studies correlating the ability of the AFS classification in predicting the presence and severity of GERD.
Glucocorticoids mediate transcriptome‐wide alternative polyadenylation: Potential mechanistic and clinical implications
Nguyen, Thanh Thanh L. , Liu, Duan , Gao, Huanyao , Ye, Zhenqing, Lee, Jeong‐Heon , Yu, Jia , Zhang, Lingxin , Wang, Liewei , Ördög, Tamás , Weinshilboum, Richard M. , Wang, Liewei , Ordog, Tamas , Weinshilboum, Richard M. , Nguyen, Thanh Thanh L. , Lee, Jeong-Heon , Liu, Duan , Wei, Lixuan

Mayo Clinic

Clinical and Translational Science | September 21, 2022 | Volume: 15 | Issue: 11 | Pages: 2758-2771

10.1111/cts.13402 | PMID 36128656 Get It

AbstractAlternative polyadenylation (APA) is a common genetic regulatory mechanism that generates distinct 3′ ends for RNA transcripts. Changes in APA have been associated with multiple biological processes and disease phenotypes. However, the role of hormones and their drug analogs in APA remains largely unknown. In this study, we investigated transcriptome‐wide the impact of glucocorticoids on APA in 30 human B‐lymphoblastoid cell lines. We found that glucocorticoids could regulate APA for a subset of genes, possibly by changing the expression of 142 RNA‐binding proteins, some with known APA‐regulating properties. Interestingly, genes with glucocorticoid‐mediated APA were enriched in viral translation‐related pathways, while genes with glucocorticoid‐mediated expression were enriched in interferon and interleukin pathways, suggesting that glucocorticoid‐mediated APA might result in functional consequences distinct from gene expression. For example, glucocorticoids, a pharmacotherapy for severe COVID‐19, were found to change the APA but not the expression of LY6E, an important antiviral inhibitor in coronavirus diseases. Glucocorticoid‐mediated APA was also cell‐type‐specific, suggesting an action of glucocorticoids that may be unique to immune regulation. We also observed evidence for genotype‐dependent glucocorticoid‐mediated APA (referred to as pharmacogenomic‐alterative polyadenylation quantitative trait loci), providing potential functional mechanisms for a series of common genetic variants that had previously been associated with immune disorders, but without a clear mechanism. In summary, this study reports a series of observations regarding the impact of glucocorticoids on APA, raising the possibility that this mechanism might have implications for both disease pathophysiology and drug therapy.
Transfer learning identifies in vivo senescence heterogeneity and contributions to vascularization and matrix production across species and diverse pathologies
Stivers, Katlin B. , Gray-Gaillard, Elise , Ruta, Anna , Hamada, Naomi, Hamada, Masakazu , Trewartha, Shawn , Wolf, Matthew, Keerthivasan, Shilpa , Saux, Claude Le, Housseau, Franck , Deursen, Jan M. van , Pardoll, Drew, Elisseeff, Jennifer H. , Cherry, Christopher, Andorko, James I. , Krishnan, Kavita , Mejías, Joscelyn C. , Nguyen, Helen Hieu , Han, Jin , Hamada, Naomi, Hamada, Masakazu, Sturmlechner, Ines , Michel, John H. , Huyer, Locke Davenport , Tam, Ada J , Peña, Alexis N. , Fertig, Elana Judith , Baker, Darren J.

Mayo Clinic

No container title available | September 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1847932/v1 Get It

Abstract Cellular senescence is a state of permanent growth arrest that plays an important role in wound healing, tissue fibrosis, and tumor suppression. Despite senescent cells’ (SnC) pathological role and therapeutic interest, their phenotype in vivo remains poorly defined. Here, we developed an in vivoderived senescence signature using a foreign body response (FBR) fibrosis model in a SnC reporter mouse. We identified pericytes and “cartilage-like” fibroblasts as senescent and defined cell typespecific senescence associated secretory phenotypes (SASP). Transfer learning and senescence scoring identified these two SnC populations along with endothelial and epithelial SnCs in new and publicly available murine and human data single cell RNAseq (scRNAseq) datasets from diverse pathologies. Signaling analysis uncovered crosstalk between SnCs and myeloid cells via an IL34- CSF1R-TGFßR signaling axis, contributing to tissue balance of vascularization and matrix production. Overall, our study provides a senescence signature and a computational approach that may be broadly applied to identify transcriptional profiles and SASP factors produced by SnCs that regulate tissue structure and pathology.
Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences
Nguyen, Thanh Thanh L. , Wang, Min , Liu, Duan , Bonilla, Hilda Mariana Gonzalez , Acker, Nancy, Murthy, Vishakantha , Shrivastava, Sanskriti , Desai, Viral , Burnett, John C. , Redfield, Margaret M. , Bailey, Kent R. , Weinshilboum, Richard M. , Pereira, Naveen L. , Iyer, Seethalakshmi , Gonzalez Bonilla, Hilda Mariana, Desai, Viral K , Redfield, Margaret, Pereira, Naveen L , Nguyen, Thanh Thanh L. , Wang, Min , Liu, Duan , Weinshilboum, Richard M.

Mayo Clinic

Circulation: Heart Failure | September 20, 2022 | Volume: 15 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.122.009629 | PMID 35656806 Get It

Gaps in hepatocellular carcinoma surveillance in a United States cohort of insured patients with cirrhosis
Nguyen, Mindie H. , Roberts, Lewis R. , Engel-Nitz, Nicole, Bancroft, Tim , Roberts, Lewis R , Ozbay, A. Burak , Singal, Amit G.

Mayo Clinic

Current Medical Research and Opinion | September 16, 2022 | Volume: 38 | Issue: 12 | Pages: 2163-2173

10.1080/03007995.2022.2124070 | PMID 36111416 Get It

Imaging of pediatric liver tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper
Infante, Juan C. , Acord, Michael R. , Davis, James C. , Khanna, Geetika , Morani, Ajaykumar C. , Morin, Cara E. , Nguyen, HaiThuy N. , Rees, Mitchell A. , Squires, Judy , Tang, Elizabeth , Thacker, Paul G. , Towbin, Alexander J. , Schooler, Gary R. , Alazraki, Adina , Chavhan, Govind B. , Davis, James Christopher, Shaikh, Raja , Srinivasan, Abhay S.

Mayo Clinic

Pediatric Blood & Cancer | September 14, 2022 | Volume: 70 | Issue: S4 | Pages: No page available

10.1002/pbc.29965 | PMID 36102690 Get It

AbstractPrimary hepatic malignancies are relatively rare in the pediatric population, accounting for approximately 1%–2% of all pediatric tumors. Hepatoblastoma and hepatocellular carcinoma are the most common primary liver malignancies in children under the age of 5 years and over the age of 10 years, respectively. This paper provides consensus‐based imaging recommendations for evaluation of patients with primary hepatic malignancies at diagnosis and follow‐up during and after therapy.
MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls
Gaudioso, Cristina , Mar, Soe , Casper, T. Charles , Codden, Rachel , Nguyen, Adam, Aaen, Gregory , Chitnis, Tanuja , Francisco, Carla , Gorman, Mark , Greenberg, Benjamin , Hart, Janace, Lotze, Timothy , Narula, Sona , Pittock, Sean J. , Rose, John , Schreiner, Teri , Tillema, Jan‐Mendelt , Wheeler, Yolanda , Gaudioso, Cristina M , Chitnis, Tanuja , Graves, Jennifer , Pittock, S J , Waubant, Emmanuelle L. , Greenberg, Benjamin M , Nguyen, Adam, Benson, Leslie, Goyal, Manu S. , Graves, Jennifer , Krupp, Lauren , Rensel, Mary R. , Rodriguez, Moses , Schreiner, Teri , Waldman, Amy , Weinstock‐Guttman, Bianca , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | September 11, 2022 | Volume: 93 | Issue: 2 | Pages: 271-284

10.1002/ana.26502 | PMID 36088544 Get It

Objective The purpose of this study was to determine the frequency of myelin oligodendrocyte glycoprotein (MOG)‐IgG and aquaporin‐4 (AQP4)‐IgG among patients with pediatric‐onset multiple sclerosis (POMS) and healthy controls, to determine whether seropositive cases fulfilled their respective diagnostic criteria, to compare characteristics and outcomes in children with POMS versus MOG‐IgG‐associated disease (MOGAD), and identify clinical features associated with final diagnosis. Methods Patients with POMS and healthy controls were enrolled at 14 US sites through a prospective case–control study on POMS risk factors. Serum AQP4‐IgG and MOG‐IgG were assessed using live cell‐based assays. Results AQP4‐IgG was negative among all 1,196 participants, 493 with POMS and 703 healthy controls. MOG‐IgG was positive in 30 of 493 cases (6%) and zero controls. Twenty‐five of 30 patients positive with MOG‐IgG (83%) had MOGAD, whereas 5 of 30 (17%) maintained a diagnosis of multiple sclerosis (MS) on re‐review of records. MOGAD cases were more commonly in female patients (21/25 [84%] vs 301/468 [64%]; p = 0.044), younger age (mean = 8.2 ± 4.2 vs 14.7 ± 2.6 years; p < 0.001), more commonly had initial optic nerve symptoms (16/25 [64%] vs 129/391 [33%]; p = 0.002), or acute disseminated encephalomyelitis (ADEM; 8/25 [32%] vs 9/468 [2%]; p < 0.001), and less commonly had initial spinal cord symptoms (3/20 [15%] vs 194/381 [51%]; p = 0.002), serum Epstein–Barr virus (EBV) positivity (11/25 [44%] vs 445/468 [95%]; p < 0.001), or cerebrospinal fluid oligoclonal bands (5/25 [20%] vs 243/352 [69%]; p < 0.001). Interpretation MOG‐IgG and AQP4‐IgG were not identified among healthy controls confirming their high specificity for pediatric central nervous system (CNS) demyelinating disease. Five percent of those with prior POMS diagnoses ultimately had MOGAD; and none had AQP4‐IgG positivity. Clinical features associated with a final diagnosis of MOGAD in those with suspected MS included initial ADEM phenotype, younger age at disease onset, and lack of EBV exposure. ANN NEUROL 2023;93:271–284
Surgical treatment of brain arteriovenous malformations: clinical outcomes of patients included in the registry of a pragmatic randomized trial
Darsaut, Tim E. , Magro, Elsa, Bojanowski, Michel W., Chaalala, Chiraz , Nico, Lorena , Bacchus, Emma, Klink, Ruby , Sabatier, Jean-François, Januel, Anne-Christine , Pélissou-Guyotat, I., Roche, Pièrre-Hugues , Brunel, Hervé, Proust, F. , Cornu, Philippe, Gaberel, Thomas , Barbier, Charlotte , Corre, Marine Le, Costalat, Vincent , Jecko, Vincent , Barreau, Xavier , Gauvrit, Jean‐Yves , Derrey, Stéphane , Papagiannaki, Chrysanthi , Abdalkader, Mohamad , Viard, Geraldine, Raymond, Jean , _, _, _, _, Chow, Michael M. C., Findlay, J. Max , Lesiuk, Howard , Drake, Brian , Santos, Marlene dos, Seizeur, Romuald, Pradier, Olivier, Ognard, Julien, Aouni, Mourad Cheddad El , Boursier, Romain, Thillays, F. , Roualdes, Vincent , Calvière, Lionel , Gauvrit, J.Y., Lecouillard, Isabelle, Nouhaud, Elodie, Raoult, Hélène , Eugene, François, Paya, Christophe, Ronzière, Thomas , Trystram, D. , Naggara, Olivier, Emery, Évelyne , Pellisou-Guyotat, Isabelle, Guyotat, Jacques, Berhouma, Monsef, Riva, Roberto, Biondi, Alessandra , Thines, L. , Bougaci, Nassim , Bracard, Serge, Anxionnat, René , Bernier‐Chastagner, Valérie , Civit, Thierry, Penchet, Guillaume, Gimbert, Edouard, Marnat, Gaulthier, Huchet, Aymeri, Herbreteau, Denis , Bibi, Richard, Ifergan, Héloïse , Janot, Kévin, Peyrière, Hadrien, Kaya, Jean-Marc, Touta, Adamou, Troude, Lucas, Boissonneau, Sébastien , Boch, Anne‐Laure , Clarençon, Frédéric , Nouet, Aurélien , Premat, Kévin, Gascou, Gregory, Lefevre, Pierre-Henri, Riquelme, Carlos , Cébula, H. , Ollivier, Irène , Pop, Raoul, Spatola, Giorgio, Chalumeau, Vanessa, Ikka, Léon , Ozanne, Augustin , Caroff, Jildaz, Chabert, Emmanuel , Rouchaud, Aymeric, Caire, François, Ricolfi, F. , Cao, Catherine, Mourier, Klaus-Luc, Thouant, Pierre, Farah, Walid, Carlson, Andrew P. , Silva, Luciana Alves Oliveira, Froio, Nayara de Lima, Mont’Alverne, Francisco J. A., Martins, Jose Luri, Mendes, George Nilton Nunes , Miranda, Rodrigo Rivera, Rouchaud, Aymeric , Rivera, Rodrigo , Ognard, Julien , Shotar, Eimad , Rouchaud, Aymeric , Ognard, Julien , Bojanowski, Michel W. , Iancu, Daniela , Weill, Alain , Roy, Daniel C. , Cognard, Christophe , Eker, Omer , Graillon, Thomas , Beaujeux, Rémy , Aldéa, Sorin , Piotin, Michel , Shotar, Eimad , Corre, Marine Le, Morandi, Xavier , Nguyen, Thanh N. , Tawk, Rabih G. , Huynh, Thien , Gévry, Guylaine , Gentric, Jean‐Christophe , _, _, _, _, Rempel, Jeremy L , O'Kelly, Cian J , Fahed, Robert , Santos, Marlene dos, Nonent, Michel , Timsit, Serge , Desal, Hubert , Blanc, Raphaël , Eugene, François, Bras, Anthony Le , Ferré, Jean‐Christophe , Paya, Christophe, Rodriguez-Régent, Christine , Kerleroux, Basile , Touzé, Emmanuel , Dumot, Chloé , Charbonnier, Guillaume , Gory, Benjamin , Boulouis, Grégoire , Velut, Stéphane , Bibi, Richard , Troude, Lucas , Sourour, Nader Antoine , Lenck, Stéphanie , Premat, Kévin , Corre, Marine Le, Bonafé, Alain , Dargazanli, Cyril , Gascou, Grégory , Lefèvre, Pierre-Henri , Pop, Raoul , Spelle, Laurent , Chalumeau, Vanessa , Gallas, Sophie , Mihalea, Cristian , Mounayer, Charbel , Thouant, Pierre , Silva, Gisele Sampaio , Montalverne, Francisco Jose

Mayo Clinic

Journal of Neurosurgery | September 9, 2022 | Volume: 138 | Issue: 4 | Pages: 891-899

10.3171/2022.7.jns22813 | PMID 36087316 Get It

OBJECTIVE The Treatment of Brain Arteriovenous Malformations Study (TOBAS) is a pragmatic study that includes 2 randomized trials and registries of treated or conservatively managed patients. The authors report the results of the surgical registry. METHODS TOBAS patients are managed according to an algorithm that combines clinical judgment and randomized allocation. For patients considered for curative treatment, clinicians selected from surgery, endovascular therapy, or radiation therapy as the primary curative method, and whether observation was a reasonable alternative. When surgery was selected and observation was deemed unreasonable, the patient was not included in the randomized controlled trial but placed in the surgical registry. The primary outcome of the trial was mRS score > 2 at 10 years (at last follow-up for the current report). Secondary outcomes include angiographic results, perioperative serious adverse events, and permanent treatment-related complications leading to mRS score > 2. RESULTS From June 2014 to May 2021, 1010 patients were recruited at 30 TOBAS centers. Surgery was selected for 229/512 patients (44%) considered for curative treatment; 77 (34%) were included in the surgery versus observation randomized trial and 152 (66%) were placed in the surgical registry. Surgical registry patients had 124/152 (82%) ruptured and 28/152 (18%) unruptured arteriovenous malformations (AVMs), with the majority categorized as low-grade Spetzler-Martin grade I–II AVM (118/152 [78%]). Thirteen patients were excluded, leaving 139 patients for analysis. Embolization was performed prior to surgery in 78/139 (56%) patients. Surgical angiographic cure was obtained in 123/139 all-grade (89%, 95% CI 82%–93%) and 105/110 low-grade (95%, 95% CI 90%–98%) AVM patients. At the mean follow-up of 18.1 months, 16 patients (12%, 95% CI 7%–18%) had reached the primary safety outcome of mRS score > 2, including 11/16 who had a baseline mRS score ≥ 3 due to previous AVM rupture. Serious adverse events occurred in 29 patients (21%, 95% CI 15%–28%). Permanent treatment-related complications leading to mRS score > 2 occurred in 6/139 patients (4%, 95% CI 2%–9%), 5 (83%) of whom had complications due to preoperative embolization. CONCLUSIONS The surgical treatment of brain AVMs in the TOBAS registry was curative in 88% of patients. The participation of more patients, surgeons, and centers in randomized trials is needed to definitively establish the role of surgery in the treatment of unruptured brain AVMs. Clinical trial registration no.: NCT02098252 (ClinicalTrials.gov)